Bronchiectasis and NTM Research Registry

A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis and/or Non-Tuberculosis Mycobacteria Patients from Major Clinical and Research Institutions

• Enrollment Status: Recruiting
• Study Type: Registry
• Intervention/Treatment: N/A
• Sponsor: COPD Foundation
• PI: Andreas Schmid, M.D.

ACT18018

A randomized, double-blind, placebo-controlled, parallelgroup, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis

• Enrollment Status: Active, not recruiting
• Study Type: Interventional (Clinical Trial)
• Intervention/Treatment: Itepekimab (anti-IL-33 mAb) / or placebo
• Sponsor: Sanofi
• PI: Andreas Schmid, M.D.

RPL554-NCFB-220

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis

• Enrollment Status: Recruiting
• Study Type: Interventional (Clinical Trial)
• Intervention/Treatment: Ensifentrine / or placebo
• Sponsor: Verona Pharma
• PI: Andreas Schmid, M.D.

Insmed Brensocatib Expanded Access Program

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

• Expanded Access Status: Available
• Study Type:Expanded Access

• Intervention/Treatment: Brensocatib
• Sponsor: Insmed Incorporated
• PI: Andreas Schmid, M.D.

NOAS

Measurement of nasal nitric oxide and exhaled nitric oxide in patients with Non-CF Bronchiectasis and chronic respiratory diseases

• Enrollment Status: Recruiting
• Study Type: Observational
• Intervention/Treatment: N/A
• Sponsor: The University of Kansas Medical Center
• PI: Andreas Schmid, M.D.

Insmed 19164

Qualitative Development and Psychometric Validation of a Clinical Outcome Assessment (COA) Tool for Bronchiectasis 

• Enrollment Status: Completed
• Study Type: Qualitative Assessment
• Intervention/Treatment: N/A
• Sponsor: Insmed Incorporated
• PI: Andreas Schmid, M.D.
  

Insmed 19145

Qualitative Interviews to Support PRO Measurement Development in Patients with Mycobacterium avium complex (MAC) or Mycobacterium abscessus (MAbs) Lung Infection

• Enrollment Status: Completed
• Study Type: Qualitative Assessment
• Intervention/Treatment: N/A
• Sponsor: Insmed Incorporated
• PI: Andreas Schmid, M.D.

INS1007-301 – ASPEN

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study

• Enrollment Status: Completed
• Study Type: Interventional (Clinical Trial)
• Intervention/Treatment: Brensocatib / or placebo
• Sponsor: Insmed Incorporated
• PI: Andreas Schmid, M.D.

D325BC00001 – MAHALE

A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)

• Enrollment Status: Completed
• Study Type: Interventional (Clinical Trial)
• Intervention/Treatment: Benralizumab / or placebo
• Sponsor: AstraZeneca
• PI: Andreas Schmid, M.D.

BI 1397-0012

A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis

• Enrollment Status: Completed
• Study Type: Interventional (Clinical Trial)
• Intervention/Treatment: BI 1291583 / or placebo
• Sponsor: Boehringer Ingelheim
• PI: Andreas Schmid, M.D.

MCC

In-vivo measurement of mucociliary clearance in Non-CF bronchiectasis patients

• Enrollment Status: Completed
• Study Type: Observational
• Intervention/Treatment: N/A
• Sponsor: The University of Kansas Medical Center
• PI: Andreas Schmid, M.D.